downgrad teva
anticip gener compani price pressur litig
endo teva ew uw although stock
under-perform concern
potenti downsid teva due brand opioid
concern prior thesi us gener price pressur
would moder earli spoke amneal manag wake
compani juli ebitda guidanc cut although amneal face
company-specif challeng concern us potenti worsen us
competit price pressur learn buy group pressur
gener price anticip includ cover ricki
goldwass contract buyer dictat price firmli
exampl buyer typic state gener price list
two gener supplier list three
gener supplier addit understand smaller/ex-u base gener
manufactur will enter market surprisingli low price
new buy group price pressur wors expect buyer
signific pressur deliv earn distributor need make
lack brand price inflat sinc buy group often
favor nation buy claus one buy group receiv lower price
spill increas competit amongst gener manufactur fda
priorit approv new gener limit competit
fewer exist gener exist player profit product face
commodit risk fda clear backlog anda gener drug
applic new gener appear will compet aggress
anticip price lower total compani ebitda follow
endo consensu
consensu teva consensu us gener exposur
see stock multipl skew downsid due lawsuit risk opioid
litig get start thousand opioid lawsuit
see potenti neg litig develop next year
teva announc opioid settlement oklahoma may juli
oklahoma opioid litig judg deni jnj cover david lewi
request throw public nuisanc claim addit gener
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
price-fix alleg expand may least state file
lawsuit alleg gener manufactur conspir artifici inflat
manipul price gener drug predict
magnitud risk note financi model reflect potenti
penalti high debt leverag financi risk like constrain
compani acquir extern growth driver litig risk appear
greatest teva given histor brand opioid sale
view teva expos opioid litig thu
downgrad underweight two compani potenti
expos opioid litig promot brand physicians/pati
concern financi leverag expect endo deliv solid
earn result face competit earn pressur long-term
teva could disappoint fail launch restasi nuvar and/or
forteo soon ew uw lower pt ev old adj
ebitda ev new lower ebitda
ebitda growth net ebitda
teva ew uw lower pt ev old ebitda
ev new adj ebitda lower ebitda
ebitda growth net ebitda
amneal promot opioid brand may less
expos litig risk thu rate equal-weight gener face
earn multipl risk d/g teva uw
lower earn estim pt maintain ow given low valuat
potenti corpor action may revisit rate board
effect posit chang see risk earn given us price pressur
poor iqvia sale trend see exhibit lower pt
old adj ebitda ev new lower
adj ebitda ebitda growth remain unchang
new ev/ebitda multipl target teva despit
lower net ebitda vs limit opioid litig exposur
brand promot like teva expect corpor updat soon
yet taken action strateg review disclos august
final juli analyst day plan follow save-the-d
announc two month ago may bull case upsid includ potenti
leadership/govern chang improv financi prospect bear case
downsid includ lower revenu earn due busi pressur
lack corpor action
left amneal rate unchang ew follow larg declin stock
lower pt ev old ebitda ev
new adj ebitda lower ebitda
ebitda growth net ebitda
could wrong stock could trade better expect gener
price pressur moder compani pay meaning debt price-fix
alleg resolv and/or opioid litig fear diminish
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
litig risk appear greatest teva given
histor brand opioid sale financi leverag
view compani histor brand opioid sale rather gener opioid
high financi leverag sensit unquantifi potenti liabil
risk particular teva face gener brand opioid
litig risk exposur promot brand opioid could potenti yield
greater litig risk gener pure-play brand repres major
compani brand opioid sale year opana er percocet
fentora actiq teva
exhibit brand opioid revenu report ceph/teva
teva fentora actiq report sale iqvia sale teva provid fentora actiq sale data acquir cephalon fentora
receiv fda approv septemb actiq receiv fda approv novemb
prior opioid litig relat report detail
teva opioid litig get start may
asid see limit risk stem on-going opioid litig
given lack brand exposur recal april conjunct
global social respons report issu statement respons opioid
epidem state regard presenc opioid market
compani limit role suppli opioid contain drug product sold
accord im data opioid portfolio consist gener product one
brand product part nation discuss opioid
intraven anesthesia medicin administ healthcar profession
surgery-cent set patient receiv prescript
promot market opioid product
similarli amneal lack brand opioid exposur investor confer june
manag state oklahoma trial brand trial around
promot market opioid product amneal perspect
particip opioid particip opioid litig gener manufactur
produc product sell product dea-approv locat
quota alloc us activ promot market
product pure provid substitut brand product
creat market particip market see
litig play
opioid relat litig costli teva announc settlement
state oklahoma may oklahoma popul repres us total
quantifi risk state separ reckitt announc
settlement juli regard addiction-fight medic suboxon april
npr articl reckitt state compani allegedli creat nationwid scheme
us design convinc doctor govern insur provid indivior
patent opioid medic safer less prone abus cheaper gener
gener price fix lawsuit gener manufactur remain overhang
least state file lawsuit alleg gener manufactur conspir
artifici inflat manipul price gener drug given
uncertainti around quantifi potenti litig liabil along headlin
risk increment details/evid releas investor assign discount
quot may cnn articl relat second gener price fix
complaint on-going expand investig includ
drug manufactur scheme increas price affect medicar medicaid
health insur market individu
lawsuit also name senior execut defend respons sale
market price oper
lawsuit specifi one report found price gener
medic increas averag juli juli
period begin juli continu januari
teva significantli rais price approxim differ gener drug
size price increas vari number well
court document say
email text messag telephon record former compani insid
believ prove multi-year conspiraci fix price divid market share
huge number gener drug said tong whose offic lead coalit
state stop compani individu orchestr
scheme held account
first complaint file us district court eastern district
pennsylvania includ corpor defend two individu defend
gener drug jason malek former presid inc
jeffrey glazer former chairman chief execut offic compani
enter plea us depart justic charg two count
crimin violat sherman anti-trust act glazer malek pay
civil penalti state cooper state investig
gener face earn multipl risk d/g teva
gener teva group current trade averag ev
ebitda driver valuat growth prospect project
ebitda compound-annual-growth-rate follow teva financi
leverag net leverag ratio net debt ebitda follow
teva litig risk four gener
stock expos opioid litig teva appear face signific
risk given histor brand opioid exposur also consid histor trade
exhibit new vs old pt ev ebitda multipl ebitda
pt
exhibit metric teva
us gener exposur consid busi mix individu compani
analyz potenti exposur us gener revenu upside/downsid rel
base ep project estim us gener revenu mix follow amneal
endo teva assum oper leverag
caus us profit swing direct revenu chang note
although endo teva less lever us price pressur amneal us
opioid litig exposur appear greater given histor promot brand opioid
us revenu miss yield us profit downsid due oper leverag
consid us gener exposur percentag total compani ep calcul total compani ep
rate amneal share equal-weight share trade low price-to-earnings earn growth
prospect unclear project compound-annual-growth-rate adj ebitda driven
pipelin contribut synergy/cost save high leverag year-end net
debt divid adj ebitda financi strateg
constraint gener price-fix opioid litig continu overhang
gener sector amneal limit exposur compar gener peer
 new pt base upon ebitda slight premium
current gener peer mean reflect slightli stronger ebitda compound-annual-growth-rate
vs gener peer teva mean low singl digit
less opioid litig risk vs gener peer brand opioid exposur
driver watch
base busi perform new product approv amneal lower
guidanc juli cite continu market pressur competit key
product gadrenaclick suppli uncertainti high season third quarter
delay key product approvals/launch includ gnuvar recal manag
previous state generic/biosimilar copaxon neulasta nuvar could
potenti approved/launch monitor base busi trend
competit develop pipelin updat
progress synergy/cost save initi newli announc restructur save
larg achiev amneal state restructur plan
expect reduc total annual cost base major mileston
expect achiev full benefit realiz
exhibit amneal iqvia us gener absolut sale yoy last month
rate endo share underweight project long-term result consensu
bearish cellulit product opportun see brand opioid litig
risk includ opana er sinc fda ask endo remov market safeti
reason materi uncertainti regard durabl key franchis
vasostrict adrenalin project compound-annual-growth-rate adj ebitda high
leverag year-end net debt divid adj ebitda
financi strateg constraint endo brand opioid litig exposur yield
greater litig risk gener pure-play
 pt base upon ebitda discount current gener
peer mean reflect compani declin ebitda prospect
signific opioid litig risk given histor brand opioid exposur
bearish view compani cellulit product opportun
driver watch
endo recent iqvia trend encourag see long-term risk believ
endo deliv solid result two profit product adrenalin
vasostrict could face competit come year current model gener
competit adrenalin franchis could face gener start
vasostrict time magnitud gener entri difficult
believ endo differenti price cch cellulit
price xiaflex activ ingredi medic indic endo plan submit
cch cellulit new bla garner differ brand name separ label
presum facilit lower price xiaflex howev given botulinum toxin
medic cosmet differ indic label nation drug code ndc
number j-code use reimburs think
xiaflex cch cellulit differenti price addit even
endo could price cch lower xiaflex endo view would limit risk
divers cch usag xiaflex indic would advers impact xiaflex
sale endo expect file bla commerci approv
background compani sell botulinum toxin sought sell
product differ price medic cosmet indic su hh
argument botulinum toxin medic cosmet two differ
biolog product us pharmacopoeia identifi separ
dc district court found botulinum toxin medic botulinum toxin cosmet
one biolog product sole activ ingredi onabotulinumtoxina
although botulinum toxin cosmet origin approv supplement
nda snda think even fda approv cch cellulit new bla hh
would like regard product xiaflex prior report
detail
exhibit endo iqvia gener absolut sale yoy last month
rate share overweight although see risk earn given us price
pressur weak iqvia sale trend maintain ow rate due low
valuat potenti corpor action caveat may revisit rate
financi prospect wors new project and/or board
effect posit corpor chang note knowledg
potenti transact project compound-annual-growth-rate adj ebitda driven new
product launch lack brand opioid litig exposur lower
financi leverag net debt adj ebitda gener peer expect
compani return modest growth de-lev balanc sheet
 pt base upon ebitda line gener peer
averag project modest ebitda compound-annual-growth-rate
appear significantli less opioid litig risk certain peer given lack
corpor govern issu may continu constrain multipl
driver watch
us revenu trend recent iqvia sale trend data concern new product
contribut increasingli benefit sale time launch bneulasta
gadvair expect launch bherceptin gener lantu
spring
ex-u perform particularli europ wake shortfal recal
adopt serial across europ result temporari busi disrupt
across europ contribut revenu miss manag convey
busi disrupt caus serial throughout europ drove neg
revenu impact quarter state disrupt behind
neg impact fact revenu lost
expect recov
exhibit mylan iqvia us gener absolut sale yoy last month
rate teva share underweight valuat appear low project long-term
result consensu see materi litig risk project compound-annual-growth-rate
adj ebitda high leverag year-end net debt divid
adj ebitda financi strateg constraint
teva pt base upon ebitda line gener
peer averag project modest ebitda compound-annual-growth-rate teva
face potenti signific gener price-fix litig risk brand opioid
litig exposur certain peer addit financi leverag
driver watch
new product launch critic us growth teva us gener growth
trajectori move forward larg depend new product
approvals/launch teva yet receiv fda approv three
potenti key gener launch restasi nuvar forteo
project teva total revenu grow margin come year copaxon
dollar declin moder ajovi austedo ramp recal earn
manag reiter stabil global gener busi
us gx rebas european gx
exhibit teva iqvia us gener absolut sale yoy last month
slight chang ev/ebitda multipl caus dramat swing
note tabl reflect base case ebitda figur
stock risk-reward page bull/bear case scenario includ higher/low
exhibit ev ebitda multipl scenario correspond impli pt teva
chg pt
chg pt
chg pt
chg pt
high leverag financi strateg constraint
exhibit project gradual de-lever forecast reflect financi liabil
associ investigations/litig risk unquantifi
wide risk reward cone reflect volatil natur stock
wide risk reward cone reflect volatil natur stock
pt base ebitda slight premium
current gener peer mean reflect less brand opioid
litig risk slightli stronger ebitda compound-annual-growth-rate
vs gener peer teva mean low-singl digit
ev/ebitda
ev/ebitda
result forecast gener price environ improv better
expect litig resolut yield upsid amneal beat
expect new product synergi revenu benefit
moder market price pressur ebitda project futur
 accret
ev/ebitda
ev/ebitda
share trade low valuat earn growth prospect unclear
high leverag also financi strateg constraint project
compound-annual-growth-rate revenue ebitda driven pipelin
contribut synergy/cost save gener price environ could
wors consensu expect litig could continu constrain
sector multipl
ev/ebitda
ev/ebitda
gener price environ deterior pipelin disappoint
unfavor resolut on-going litig buy group competit
pressur worsen drive gener busi downsid pipelin opportun
delay ebitda project neg litig newsflow hurt
share trade low price-to-earnings earn
growth prospect unclear
driven pipelin contribut
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
litig continu overhang
gener sector amneal
brand opioid exposur like
financi result rel expect
updat gener price fix opioid
extern busi develop
risk achiev price
upsid risk improv gener price
environ result expect
beat favor resolut price fix
opioid litig value-enhanc
downsid risk result
neg develop gener price
environ cost synergi miss
price-fix alleg opioid litig
wide risk reward cone reflect volatil natur stock see higher
wide risk reward cone reflect volatil natur stock see higher
probabl downsid
probabl downsid
pt base ebitda target multipl
gener peer averag given project long-term ebitda
declin high leverag litig risk
bull case ebitda
bull case ebitda
gener brand exceed expect cellulit product
success anticip opioid litig newsflow surprisingli
encourag gener xiaflex brand sale expect
drive ebitda expect cch cellulit success
differenti price vs medic indic opioid litig newsflow
encourag small expans ev drive larg equiti upsid given
base case ebitda
base case ebitda
valuat appear low project long-term result consensu
fearlitig risk assum cellulit disappoint opioid gener price
yield greater litig risk gener pure-play cch cellulit unabl
differenti price vs medic indic
bear case ebitda
bear case ebitda
financi result forecast endo abandon xialfex cellulit
opioid gener price fix litig concern grow gener sale
squeez competit pressur deterior price
environ brand xiaflex disappoint ebitda expect
multipl contract neg opioid litig newsflow
valuat appear low project long-
term result consensu see
litig risk addit signific
uncertainti regard durabl key
franchis adrenalin vasostrict
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
yield greater litig risk gener pure-
gener price trend new launch
quarterli sale momentum brand
fda action cch cellulit
risk achiev price
upsid risk base gx busi prove
resili expect gener restructur
lead profit busi
expect brand surpris upsid cch
cellulit newsflow better expect
lower debt boost price-to-earnings
sever declin project key
expect endo abandon cch
gener price-fix alleg opioid
pt base ebitda target multipl line
gener peer averag low end
trade rang project ebitda compound-annual-growth-rate
ep compound-annual-growth-rate
ev/ebitda bull case
ev/ebitda bull case ebitda
ebitda
gener trend surpris upsid posit develop strateg
improv investor percept new pipelin launch boost ebitda
forecast corpor action enhanc prospect board
surpris elimin dutch sticht current price-to-earnings constraint
ev/ebitda base case ebitda
ev/ebitda base case ebitda
return modest earn growth although near-term prospect
uncertain valuat low stock could benefit potenti
revenue ebitda ep continu make progress
de-lever balanc sheet
ev/ebitda bear case
ev/ebitda bear case ebitda
ebitda
financi wors expect due sever competit pressur
corpor action price pressur worsen morgantown facil issu
problemat disclos date new product launch
fall short expect ebitda forecast board take action
improv corpor prospect govern
although see risk near-term earn
given us price pressur poor iqvia sale
trend believ low valuat
potenti corpor action could help
stock may revisit rate
board effect materi posit
driven new product launch
lower financi leverag net
debt adj ebitda gener peer
expect continu make
progress toward de-lever balanc
litig lack brand opioid
gener industri myl-specif gener
epipen trend competit
board updat corpor strateg
review announc august
financi result guidanc updat
fda action new product applic
success new product launch
resolut price collus investig
risk achiev price
us gener environ may
deterior due competit pressur
facil issu could problemat
new launch contribut may fall short
expect due increas competit
involv may result fine claim
execut wrongdo note presid rajiv
malik mention certain press
report investig see
bloomberg articl feb
ex-u busi may fall short
opioid litig newsflow may
pt base ev/ebitda line gener
peer averag project ebitda compound-annual-growth-rate
bull case ebitda
bull case ebitda
us gener trend inflect posit ajovi revenu cost cut exceed
expect opioid litig newsflow encourag ebitda higher
base case due improv us gener trend ajovi sale upsid
higher margin manag deliv cost save forecast favor
resolut gener price fix opioid litig multipl expand
base ebitda
base ebitda
project long-term result consensu see litig risk high
leverag drive stock downsid limit visibl longer term
revenu growth prospect concern litig uncertainti
gener price price opioid continu pressur teva stock multipl
teva brand opioid litig exposur yield greater litig risk
bear ebitda
bear ebitda
earn disappoint due competit pressur execut challeng
new product launch delay unfavor resolut on-going litig
ebitda lower base case due gener shortfal ajovi key new
sheet fear weigh valuat
valuat appear low project long-
term result consensu fear
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
yield greater litig risk gener
new product austedo ajovi sale
flow trend de-lever
gener price fix opioid litig
risk achiev price
copaxon sale higher/low
opioid litig newsflow
 receiv positively/neg
sector comp valuat
exhibit spec bx gx comp
us specialti brand gener
price
spec brand gx mean
spec brand gx median
price
morgan stanley research estim thomson reuter valuat methodolog risk associ price target referenc
research report pleas contact client support follow
sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
